![Alborz Yazdi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Alborz Yazdi
Gründer bei Exavir Therapeutics
Aktive Positionen von Alborz Yazdi
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Exavir Therapeutics
![]() Exavir Therapeutics Miscellaneous Commercial ServicesCommercial Services Exavir Therapeutics is an American preclinical stage biotechnology company founded by Alborz Yazdi, Howard E. Gendelman, Benson Edagwa, dedicated to developing ultra-long-acting therapeutics for patients with chronic viral infections and central nervous system disorders. The company's pipeline includes several long-acting antiviral nanomedicines as well as an earlier stage HIV cure program that utilizes CRISPR nucleases and proprietary LNP formulations to precisely deliver pro-viral DNA excision payloads to tissues that are the target of HIV. The company aims to eliminate HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics. HIV is one of the world's most serious public health challenges, and Exavir Therapeutics is developing ultra-long-acting nanomedicines for HIV, other viral infections, and CNS disorders. | Gründer | - | - |
Präsident | - | - |
Karriereverlauf von Alborz Yazdi
Ehemalige bekannte Positionen von Alborz Yazdi
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Passaic Capital Management LLC
![]() Passaic Capital Management LLC Investment ManagersFinance Passaic Capital Management LLC (Passaic Capital) is an alternative investment firm headquartered in Albany, New York. The firm was founded in 2013 as a hedge fund platform of Millennium Management LLC. Passaic Capital manages a long/short equity portfolio for high net worth investors. | Analyst-Equity | 01.10.2020 | 01.02.2022 |
Bain Capital Life Sciences LP
![]() Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences LP (Bain Capital Life Sciences) is a private equity subsidiary of Bain Capital Private Equity LP, ultimately held by Bain Capital Holdings LP, founded in 2016. The firm is headquartered in Boston, Massachusetts. | Private-Equity-Analyst | 01.01.2019 | 01.10.2020 |
Ausbildung von Alborz Yazdi
Yale University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Private Equity Analyst | 1 |
Undergraduate Degree | 1 |
Analyst-Equity | 1 |
Sektoral
Finance | 3 |
Consumer Services | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Bain Capital Life Sciences LP
![]() Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences LP (Bain Capital Life Sciences) is a private equity subsidiary of Bain Capital Private Equity LP, ultimately held by Bain Capital Holdings LP, founded in 2016. The firm is headquartered in Boston, Massachusetts. | Finance |
Passaic Capital Management LLC
![]() Passaic Capital Management LLC Investment ManagersFinance Passaic Capital Management LLC (Passaic Capital) is an alternative investment firm headquartered in Albany, New York. The firm was founded in 2013 as a hedge fund platform of Millennium Management LLC. Passaic Capital manages a long/short equity portfolio for high net worth investors. | Finance |
Exavir Therapeutics
![]() Exavir Therapeutics Miscellaneous Commercial ServicesCommercial Services Exavir Therapeutics is an American preclinical stage biotechnology company founded by Alborz Yazdi, Howard E. Gendelman, Benson Edagwa, dedicated to developing ultra-long-acting therapeutics for patients with chronic viral infections and central nervous system disorders. The company's pipeline includes several long-acting antiviral nanomedicines as well as an earlier stage HIV cure program that utilizes CRISPR nucleases and proprietary LNP formulations to precisely deliver pro-viral DNA excision payloads to tissues that are the target of HIV. The company aims to eliminate HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics. HIV is one of the world's most serious public health challenges, and Exavir Therapeutics is developing ultra-long-acting nanomedicines for HIV, other viral infections, and CNS disorders. | Commercial Services |
- Börse
- Insiders
- Alborz Yazdi
- Erfahrung